Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

10.27USD
21 Apr 2015
Change (% chg)

$0.22 (+2.19%)
Prev Close
$10.05
Open
$10.14
Day's High
$10.27
Day's Low
$10.14
Volume
18,295
Avg. Vol
200,702
52-wk High
$16.49
52-wk Low
$8.34

VNDA.OQ

Chart for VNDA.OQ

About

Vanda Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders. The Company’s product portfolio includes: HETLIOZ (tasimelteon), a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24); Fanapt (iloperidon... (more)

Overall

Beta: 1.94
Market Cap(Mil.): $418.49
Shares Outstanding(Mil.): 41.64
Dividend: --
Yield (%): --

Financials

  VNDA.OQ Industry Sector
P/E (TTM): 32.92 153.35 41.37
EPS (TTM): 0.31 -- --
ROI: 14.71 -0.99 16.13
ROE: 19.70 -2.96 16.96
Search Stocks

Vanda's eczema drug fails mid-stage study, shares fall

- Vanda Pharmaceuticals Inc said its experimental atopic dermatitis drug failed a mid-stage study to treat chronic itching.

04 Mar 2015

UPDATE 1-Vanda's eczema drug fails mid-stage study, shares fall

March 4 - Vanda Pharmaceuticals Inc said its experimental atopic dermatitis drug failed a mid-stage study to treat chronic itching.

04 Mar 2015

Vanda's eczema drug fails mid-stage study

March 4 - Vanda Pharmaceuticals Inc said its experimental atopic dermatitis drug failed a mid-stage study to treat chronic itching, sending its shares down 8.7 percent in after-hours trading.

04 Mar 2015

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks